1. Structural Basis of Inhibition of Insulin-Regulated Aminopeptidase by a Macrocyclic Peptidic Inhibitor
- Author
-
Zachary Maben, Mats Larhed, Efstratios Stratikos, Lawrence J. Stern, Emmanuel N. Saridakis, Mathias Hallberg, Petros Giastas, and Anastasia Mpakali
- Subjects
chemistry.chemical_classification ,Vasopressin ,Conformational change ,010405 organic chemistry ,Chemistry ,Stereochemistry ,Organic Chemistry ,Closed conformation ,01 natural sciences ,Biochemistry ,Aminopeptidase ,Transmembrane protein ,0104 chemical sciences ,Angiotensin IV ,010404 medicinal & biomolecular chemistry ,Enzyme ,Drug Discovery ,Insulin regulated aminopeptidase - Abstract
[Image: see text] Insulin-regulated aminopeptidase (IRAP) is a transmembrane zinc metallopeptidase with many important biological functions and an emerging pharmacological target. Although previous structural studies have given insight on how IRAP recognizes linear peptides, how it recognizes its physiological cyclic ligands remains elusive. Here, we report the first crystal structure of IRAP with the macrocyclic peptide inhibitor HA08 that combines structural elements from angiotensin IV and the physiological substrates oxytocin and vasopressin. The compound is found in the catalytic site in a near canonical substrate-like configuration and inhibits by a competitive mechanism. Comparison with previously solved structures of IRAP along with small-angle X-ray scattering experiments suggests that IRAP is in an open conformation in solution but undergoes a closing conformational change upon inhibitor binding. Stabilization of the closed conformation in combination with catalytic water exclusion by the tightly juxtaposed GAMEN loop is proposed as a mechanism of inhibition.
- Published
- 2020